Login
Companies $PTHS
$7.15 +$0.00 (0.0%) After hours
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc.

ir.pelthos.com

What Do They Do?

Commercializes prescription topical medicines for skin conditions, including ZELSUVMI for molluscum contagiosum, XEPI for impetigo and XEGLYZE for head lice; sells ZELSUVMI to pharmaceutical wholesalers.

How Do They Make Money?

Wholesalers pay for ZELSUVMI when it is delivered. The out-license brings revenue at license delivery and as related development work progresses.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Net product revenues
Sold outright

96%
License and collaboration revenues
Licensed
3.5%

Who Are Their Customers?

Pelthos sells ZELSUVMI to national and regional wholesalers, which supply retail drugstore chains, independent pharmacies and mail-order pharmacies.

Direct customers above 10% of revenue, FY2025
of revenue from three customers (35%, 28%, 26%)

Do Revenues Turn Into Profits?

No. It lost $43.3M in FY2025.

Operating income, FY2025
−193% of revenue
▼ −328% (Loss) vs FY2024 (−$7.6M)
Net income, FY2025
−258% of revenue
▼ −445% (Loss) vs FY2024 (−$8M)
Free cash flow, FY2025
−135% of revenue
▼ −292% (Loss) vs FY2024 (−$5.8M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +108%
vs $7.4M in Q3 FY2025
Net income
▲ +51% (Loss)
vs −$16.2M in Q3 FY2025
  • Oct 30, 2026 Agreed to merge with Castle Creek Biosciences The proposed combination would add Castle Creek's cell and gene therapy platform and D-Fi to Pelthos's skin-treatment portfolio.
  • Aug 12, 2026 Will restate first-quarter financial statements Pelthos said a debt-valuation accounting error meant its March 2026 quarter statements should no longer be relied upon.
  • May 15, 2026 Changed independent accounting firms Pelthos dismissed CBIZ and appointed Grant Thornton for fiscal 2026.
Revenue over time
Net product revenues License and collaboration revenues
$20M$10M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support